Gerresheimer (GXI) Given a €68.00 Price Target at Independent Research

Independent Research set a €68.00 ($83.95) target price on Gerresheimer (ETR:GXI) in a research report released on Thursday, February 22nd. The firm currently has a neutral rating on the stock.

A number of other research analysts also recently weighed in on the company. JPMorgan Chase & Co. set a €87.70 ($108.27) price target on Gerresheimer and gave the company a buy rating in a research note on Thursday, January 4th. Credit Suisse Group set a €75.00 ($92.59) price objective on Gerresheimer and gave the company a buy rating in a report on Wednesday, February 21st. Deutsche Bank set a €64.00 ($79.01) price objective on Gerresheimer and gave the stock a neutral rating in a report on Friday, December 1st. Hauck & Aufhaeuser set a €55.00 ($67.90) target price on shares of Gerresheimer and gave the company a sell rating in a research report on Wednesday, January 24th. Finally, equinet set a €75.00 ($92.59) target price on shares of Gerresheimer and gave the stock a neutral rating in a research report on Friday, January 19th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. Gerresheimer currently has a consensus rating of Hold and a consensus price target of €69.85 ($86.24).

Gerresheimer (ETR GXI) traded up €1.55 ($1.91) during trading on Thursday, hitting €67.00 ($82.72). The stock had a trading volume of 86,147 shares, compared to its average volume of 140,278. The stock has a market capitalization of $2,100.00 and a PE ratio of 20.87. Gerresheimer has a twelve month low of €59.97 ($74.04) and a twelve month high of €78.25 ($96.60).

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Equities Focus and is the sole property of of Equities Focus. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.equitiesfocus.com/2018/03/19/independent-research-analysts-give-gerresheimer-gxi-a-68-00-price-target.html.

Gerresheimer Company Profile

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply